Table 8.

Summary of findings for PICO 12. Assessment of cholinesterase inhibitors for post-stroke dementia.

Participants: Post-stroke cognitive impairment Settings: At least 6/12 following stroke Intervention: Rivastigmine Comparator: Placebo
Outcome	No of participants	Effect placebo (n = 25)	Effect intervention (n = 25)	Quality of evidence (GRADE)
Cognition (ADAS-Cog)	One trial, n = 50 (25 in each arm)	Mean change from baseline: −2.8 (−5.1 to 0.3)	Mean change from baseline: −0.6 (−3.1 to 1.9)	Very low a
BPSD (neuropsychiatric inventory)	One trial, n = 50 (25 in each arm)	Mean change from baseline: 0.1 (−2.6 to 2.9)	Mean change from baseline: −0.31 (−0.9 to 0.9)	Very low a
Adverse events	One trial, n = 50 (25 in each arm)	N (%) with AE 10 (40%)	N (%) with AE 9 (36%)	Very low a

^aDowngraded due to serious imprecision; publication bias.